ArticleOncoTargets and therapy2022

IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Retraction].

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.